Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06284590
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-08
First Post:
2024-01-26
Brief Title:
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2L19TNF in Combination With Pembrolizumab in Unresectable Melanoma Patients
Sponsor:
Philogen SpA
Organization:
Philogen SpA
Organization Data
Organization:
Philogen SpA
Class:
INDUSTRY
Study ID:
PH-ICKPD1-0221
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Philogen SpA
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |